Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
PHVS Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: April 16, 2026
Report Source: 2025 Annual Report
Pharvaris NV. Stock Analysis PHVS
United States Health Care Mid Cap Report: Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. The company is headquartered in Leiden, Zuid-Holland and currently employs 129 full-time employees. The company went IPO on 2021-02-05. The firm focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. The company is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The firm is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Read More Pharvaris NV (PHVS) Chart
Key Statistics of Pharvaris NV (PHVS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$32.95Volume
326.67KP/E Ratio (TTM)
-52 Week Range
Market Cap
2.00BAvg. Volume
324.41KDividend Yield
-Financial Metrics & Statements of Pharvaris NV (PHVS)
FAQ's for Pharvaris NV (PHVS)
- According to Musaffa’s Shariah screening methodology, Pharvaris NV (PHVS) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Pharvaris NV using these criteria to determine its compliance status.
- Muslim investors may consider investing in Pharvaris NV if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Pharvaris NV by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Pharvaris NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Pharvaris NV on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.